Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: A phase II study from the North Central Cancer Treatment Group

Annals of Oncology

Volumn 17, Issue 4, 2006, Pages 652-656

  Giordano, K F ^a   Jatoi, Aminah ^a   Stella, P J ^b   Foster, N ^a   Tschetter, L K ^c   Alberts, S R ^a   Dakhil, S R ^d   Mailliard, J A ^e   Flynn, P J ^f   Nikcevich, D A ^g  

^a MAYO CLINIC   (United States)

^b Michigan Cancer Research Consortium   (United States)

^c Sioux Valley Clinic   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^f Metro Minnesota Community Clinical Oncology Program   (United States)

^g Duluth CCOP   (United States)

Author keywords

Capecitabine; Chemotherapy; Docetaxel; Gastric cancer; Gastroesophageal Junction; Stomach

Indexed keywords

CAPECITABINE; DOCETAXEL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYSPNEA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOKALEMIA; INFECTION; MALE; METASTASIS; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRESCRIPTION; PRIORITY JOURNAL; SCORING SYSTEM; SENSORY NEUROPATHY; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOSIS; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TAXOIDS;

EID: 33645315211     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl005     Document Type: Article

References (17)

1. Ries LA, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975-2001. Bethesda, Maryland: National Cancer Institute 2004.
2. Pyrhonen S, Kuitenen T, Nyandoto P et al. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate plus supportive care versus supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
3. Murad AM, Snatiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
4. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
5. Koizumi W, Taguchi T. A phase II study of capecitabine in patients with advanced/metastatic gastric carcinoma. Proc Soc Clin Oncol 2001; 2320A.
6. Graziano F, Catalano V, Baldelli AM et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263-1266.
7. Sulkes A, Smyth J, Sessa C et al. Docetaxel in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380-383.
8. Kodera Y, Fujiwara M, Yokoyama H et al. Combination of oral fluoropyrimidine and docetaxel: Reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo 2005; 19: 861-866.
9. Chun JH, Kim HK, Lee JS et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28: 188-194.
10. Kim JG, Sohn SK, Kim DH et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-195.
11. Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic esophageal cancer: Final results from a phase II trial. Br J Cancer 2005; 92: 2129-2133.
12. Park YH, Ryoo BY, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004; 90: 1329-1333.
13. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomized, controlled trial (the MAGIC trial). Proc of the Am Society of Clin Oncol 2005; 4001.
14. Fleming TR. One sample multiple testing procedures for phase II clinical trials. Biometrics 1982; 43: 143-151.
15. Duffy D, Santner T. Confidence intervals for a binomial parameter based on multi-stage tests. Biometrics 1987; 43: 81-93.
16. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Thuss-Patience PC, Kretzschmar A, Repp M et al. Docetaxel and continuous infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil in advanced gastric adenocarcinoma: A randomized phase II study. J Clin Oncol 2005; 23: 494-501.